Daniel Peraza, MD
Dermatology · Claremont, NHNPI 1073635355
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,935 of the $6,537 with a category attached, or 90.8%. Merck accounts for 63.3% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2022 at $2,422 and has fallen 91.6% since, to $203 in 2025.
Across 47 payments — averaging $139.08 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$4K
- AbbVie$2K
- Johnson & Johnson$342
- Galderma Laboratories, L.p.$170
- Sanofi$22
- LEO Pharma Inc.$20
- plus $48 from 3 others
What the payments were for
- Consulting fees$5,93591%
- Food & beverage$5869%
- Education$150%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 9 | $4,135 |
| AbbVie | 2 | $1,800 |
| Johnson & Johnson | 14 | $342 |
| Galderma Laboratories, L.p. | 17 | $170 |
| Sanofi | 1 | $22 |
| LEO Pharma Inc. | 1 | $20 |
| Mimedx Group, Inc. | 1 | $20 |
| Pfizer | 1 | $15 |
| DUSA Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- BOTOX$1,800
How this compares
$6,537 in reported general payments places this provider in the 75th percentile of 75 dermatology providers in New Hampshire.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Dupixent PenDupilumab | 57 | $227,198 |
| Acitretin | 24 | $4,634 |
| Mycophenolate Mofetil | 52 | $4,611 |
| Tacrolimus | 52 | $4,024 |
| Calcipotriene | 26 | $3,194 |
| Halobetasol Propionate | 54 | $2,717 |
| Minoxidil | 132 | $2,531 |
| Triamcinolone Acetonide | 175 | $2,097 |
| Clobetasol Propionate | 56 | $2,033 |
| Econazole Nitrate | 52 | $1,885 |
| Metronidazole | 29 | $1,404 |
| Fluorouracil | 16 | $1,109 |
| Ketoconazole | 25 | $1,096 |
| Betamethasone Dipropionate | 15 | $1,053 |
| Acyclovir | 18 | $940 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Claremont
- Jose PerazaClaremont$140
- Abel JarellPortsmouth$2.3M
- Robert PosnickNashua$951K
- David PosnickNashua$203K
- Yulianna RussakLebanon$170K
- Peter JenkinManchester$117K
- Neera NathanLondonderry$83K
- Michael LichterNashua$53K
- Michael ChapmanLebanon$39K
- Jennifer SteadBedford$30K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.